Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, the need for liver transplant and premature mortality.

What began as a small team of researchers in Conshohocken, Pennsylvania, U.S., is now a fully integrated biopharmaceutical company with more than 900 employees in the United States and Europe with a UK team headquartered in Paddington, London.

United by a single purpose—to lead the fight against MASH—Madrigal has built the leading clinical development program in this field.

Madrigal aims to support health systems and patients living with MASH through our innovations before the devastating complications of advanced liver disease occur. By partnering with healthcare providers and the patient community, we aim to educate, empower and advocate for those impacted by MASH.

MED-UK–2600007| Date of preparation: March 2026